{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T23:14:57Z","timestamp":1715296497652},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,4,27]],"date-time":"2013-04-27T00:00:00Z","timestamp":1367020800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s11934-013-0326-9","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T12:07:18Z","timestamp":1367410038000},"page":"227-234","source":"Crossref","is-referenced-by-count":7,"title":["Botulinum Toxin\u2014What Urologic Uses Does the Data Support?"],"prefix":"10.1007","volume":"14","author":[{"given":"J.","family":"Seth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,27]]},"reference":[{"issue":"1","key":"326_CR1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/nau.20870","volume":"29","author":"P Abrams","year":"2010","unstructured":"Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213\u201340.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"326_CR2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.eururo.2012.09.023","volume":"62","author":"MG Lucas","year":"2012","unstructured":"Lucas MG, Bosch RJ, Burkhard FC, Cruz F, Madden TB, Nambiar AK, et al. EAU guidelines on surgical treatment of urinary incontinence. Eur Urol. 2012;62(6):1118\u201329.","journal-title":"Eur Urol"},{"issue":"4","key":"326_CR3","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"\u2022 Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742\u201350. Large phase III RCT in NDO pts with MS and SCI showing good efficacy for 200 and 300 U OnabotulinumtoxinA..","journal-title":"Eur Urol"},{"issue":"6","key":"326_CR4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"\u2022 Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase III efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131\u20139. Large phase III multi-centre RCT of NDO pts with MS and SCI showing good efficacy of 200 and 300 U OnabotulinumtoxinA..","journal-title":"J Urol"},{"key":"326_CR5","author":"E Rovner","year":"2013","unstructured":"Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013. doi: 10.1002\/nau.22376 .","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"326_CR6","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","volume":"185","author":"S Herschorn","year":"2011","unstructured":"Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229\u201335.","journal-title":"J Urol"},{"issue":"5","key":"326_CR7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1590\/S1677-55382011000500012","volume":"37","author":"S Deffontaines-Rufin","year":"2011","unstructured":"Deffontaines-Rufin S, Weil M, Verollet D, Peyrat L, Amarenco G. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol. 2011;37(5):642\u20138.","journal-title":"Int Braz J Urol"},{"issue":"3","key":"326_CR8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","volume":"81","author":"M Kennelly","year":"2013","unstructured":"\u2022 Kennelly M, Dmochowski R, Ethans K, Karsenty G, Schulte-Baukloh H, Jenkins B, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence Due to neurogenic detrusor overactivity: an interim analysis. Urology. 2013;81(3):491\u20137. Efficacy of repeated injections of BTX-A in NDO patients..","journal-title":"Urology"},{"issue":"1","key":"326_CR9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1442-2042.2012.03218.x","volume":"20","author":"K Hikita","year":"2013","unstructured":"Hikita K, Honda M, Kawamoto B, Panagiota T, Inoue S, Hinata N, et al. Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients. Int J Urol. 2013;20(1):94\u20139.","journal-title":"Int J Urol"},{"issue":"4","key":"326_CR10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.juro.2010.12.002","volume":"185","author":"S Khan","year":"2011","unstructured":"Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185(4):1344\u20139.","journal-title":"J Urol"},{"issue":"3","key":"326_CR11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","volume":"186","author":"A Giannantoni","year":"2011","unstructured":"Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011;186(3):960\u20134.","journal-title":"J Urol"},{"key":"326_CR12","doi-asserted-by":"crossref","unstructured":"Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242\u20139.","DOI":"10.1002\/nau.22293"},{"issue":"8","key":"326_CR13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/nau.21146","volume":"30","author":"HC Kuo","year":"2011","unstructured":"Kuo HC, Liu SH. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries. Neurourol Urodyn. 2011;30(8):1541\u20135.","journal-title":"Neurourol Urodyn"},{"key":"326_CR14","doi-asserted-by":"crossref","unstructured":"Jia C, Liao LM, Chen G, Sui Y. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury. Spinal Cord. 2013. doi: 10.1038\/sc.2012.180 .","DOI":"10.1038\/sc.2012.180"},{"key":"326_CR15","doi-asserted-by":"crossref","unstructured":"\u2022 Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C et al. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase III Randomized Placebo-Controlled Trial. J Urol. 2012. doi: 10.1016\/j.juro.2012.12.022 . Large phase III RCT assessing OnabotulinumtoxinA at 100 U\u00a0verus placebo.","DOI":"10.1016\/j.juro.2012.12.022"},{"issue":"19","key":"326_CR16","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","volume":"367","author":"AG Visco","year":"2012","unstructured":"Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"326_CR17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","volume":"62","author":"CJ Fowler","year":"2012","unstructured":"Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148\u201357.","journal-title":"Eur Urol"},{"issue":"4","key":"326_CR18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","volume":"30","author":"E Rovner","year":"2011","unstructured":"Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30(4):556\u201362.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"326_CR19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","volume":"62","author":"DG Tincello","year":"2012","unstructured":"Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol. 2012;62(3):507\u201314.","journal-title":"Eur Urol"},{"issue":"4","key":"326_CR20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","volume":"61","author":"C Dowson","year":"2012","unstructured":"Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012;61(4):834\u20139.","journal-title":"Eur Urol"},{"issue":"11","key":"326_CR21","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/j.1464-410X.2010.09791.x","volume":"107","author":"X Game","year":"2011","unstructured":"Game X, Khan S, Panicker JN, Kalsi V, Dalton C, Elneil S, et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU Int. 2011;107(11):1786\u201392.","journal-title":"BJU Int"},{"issue":"4","key":"326_CR22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00404-012-2349-8","volume":"286","author":"R Granese","year":"2012","unstructured":"Granese R, Adile G, Gugliotta G, Cucinella G, Saitta S, Adile B. Botox((R)) for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection. Arch Gynecol Obstet. 2012;286(4):923\u20139.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"326_CR23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","volume":"111","author":"A Mohee","year":"2013","unstructured":"Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106\u201313.","journal-title":"BJU Int"},{"issue":"4","key":"326_CR24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1464-410X.2006.06063.x","volume":"97","author":"A Sahai","year":"2006","unstructured":"Sahai A, Kalsi V, Khan MS, Fowler CJ. Techniques for the intradetrusor administration of botulinum toxin. BJU Int. 2006;97(4):675\u20138.","journal-title":"BJU Int"},{"issue":"5","key":"326_CR25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.eururo.2011.10.043","volume":"61","author":"RP Manecksha","year":"2012","unstructured":"Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol. 2012;61(5):928\u201335.","journal-title":"Eur Urol"},{"issue":"3","key":"326_CR26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00345-011-0736-6","volume":"30","author":"SH Alloussi","year":"2012","unstructured":"Alloussi SH, Lang C, Eichel R, Al-Kaabneh A, Seibold J, Schwentner C, et al. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. World J Urol. 2012;30(3):367\u201373.","journal-title":"World J Urol"},{"issue":"12","key":"326_CR27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sc.2012.76","volume":"50","author":"J Krhut","year":"2012","unstructured":"Krhut J, Samal V, Nemec D, Zvara P. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord. 2012;50(12):904\u20137.","journal-title":"Spinal Cord"},{"issue":"7","key":"326_CR28","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/nau.21054","volume":"30","author":"H-C Kuo","year":"2011","unstructured":"\u2022 Kuo H-C. Bladder base\/trigone injection is safe and as effective as bladder body injection of OnabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30(7):1242\u20138. Open label study assessing different BTX-A injection techniques in the bladder..","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"326_CR29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00345-010-0618-3","volume":"29","author":"P Padmanabhan","year":"2011","unstructured":"Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, Penson DF. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol. 2011;29(1):51\u20137.","journal-title":"World J Urol"},{"issue":"4","key":"326_CR30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1464-410X.2010.09905.x","volume":"108","author":"RK Leong","year":"2011","unstructured":"Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int. 2011;108(4):558\u201364.","journal-title":"BJU Int"},{"issue":"2","key":"326_CR31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jval.2010.08.006","volume":"14","author":"S Arlandis","year":"2011","unstructured":"Arlandis S, Castro D, Errando C, Fernandez E, Jimenez M, Gonzalez P, et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Value Health. 2011;14(2):219\u201328.","journal-title":"Value Health"},{"issue":"2","key":"326_CR32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","volume":"62","author":"G Maria","year":"2003","unstructured":"Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003;62(2):259\u201364. discussion 64-5.","journal-title":"Urology"},{"issue":"3","key":"326_CR33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.juro.2011.04.062","volume":"186","author":"ED Crawford","year":"2011","unstructured":"Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011;186(3):965\u201370.","journal-title":"J Urol"},{"key":"326_CR34","doi-asserted-by":"crossref","first-page":"463574","DOI":"10.1100\/2012\/463574","volume":"2012","author":"R Arnouk","year":"2012","unstructured":"Arnouk R, Suzuki Bellucci CH, Benatuil Stull R, de Bessa Jr J, Malave CA, Mendes Gomes C. Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. Sci World J. 2012;2012:463574. doi: 10.1100\/2012\/463574 .","journal-title":"Sci World J"},{"issue":"4","key":"326_CR35","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.urology.2012.06.004","volume":"80","author":"LM Kort de","year":"2012","unstructured":"de Kort LM, Kok ET, Jonges TN, Rosier PF, Bosch JL. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia. Urology. 2012;80(4):889\u201393.","journal-title":"Urology"},{"issue":"11 Pt C","key":"326_CR36","doi-asserted-by":"crossref","first-page":"E837","DOI":"10.1111\/j.1464-410X.2012.11288.x","volume":"110","author":"E Sacco","year":"2012","unstructured":"Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, et al. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. BJU Int. 2012;110(11 Pt C):E837\u201344.","journal-title":"BJU Int"},{"issue":"1","key":"326_CR37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00345-012-0851-z","volume":"31","author":"A Hamidi Madani","year":"2013","unstructured":"Hamidi Madani A, Enshaei A, Heidarzadeh A, Mokhtari G, Farzan A, Mohiti Asli M, et al. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol. 2013;31(1):235\u20139.","journal-title":"World J Urol"},{"issue":"3","key":"326_CR38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","volume":"63","author":"M Marberger","year":"2013","unstructured":"\u2022 Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase II dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63(3):496\u2013503. Largest RCT assessing BTX-A injections vs placebo into the prostate for BPH..","journal-title":"Eur Urol"},{"issue":"12","key":"326_CR39","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1464-410X.2010.09841.x","volume":"107","author":"J Silva","year":"2011","unstructured":"Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Silva C, et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int. 2011;107(12):1950\u20134.","journal-title":"BJU Int"},{"issue":"1","key":"326_CR40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","volume":"53","author":"JP Merwe van de","year":"2008","unstructured":"van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60\u20137.","journal-title":"Eur Urol"},{"issue":"1","key":"326_CR41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.eururo.2011.07.069","volume":"61","author":"A Giannantoni","year":"2012","unstructured":"Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29\u201353.","journal-title":"Eur Urol"},{"issue":"1","key":"326_CR42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/nau.20946","volume":"30","author":"HP Gottsch","year":"2011","unstructured":"Gottsch HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for interstitial cystitis\/painful bladder syndrome. Neurourol Urodyn. 2011;30(1):93\u20136.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"326_CR43","first-page":"197","volume":"15","author":"SD Chung","year":"2012","unstructured":"Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Phys. 2012;15(3):197\u2013202.","journal-title":"Pain Phys"},{"issue":"2","key":"326_CR44","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.juro.2012.09.027","volume":"189","author":"R Pinto","year":"2013","unstructured":"Pinto R, Lopes T, Silva J, Silva C, Dinis P, Cruz F. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome\/interstitial cystitis. J Urol. 2013;189(2):548\u201353.","journal-title":"J Urol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-013-0326-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-013-0326-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-013-0326-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T22:37:44Z","timestamp":1715294264000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-013-0326-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,27]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["326"],"URL":"https:\/\/doi.org\/10.1007\/s11934-013-0326-9","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,27]]}}}